CANADA LIFE ASSURANCE Co Has $24.80 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

CANADA LIFE ASSURANCE Co boosted its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 70,389 shares of the biotechnology company’s stock after acquiring an additional 4,110 shares during the quarter. CANADA LIFE ASSURANCE Co’s holdings in United Therapeutics were worth $24,800,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of UTHR. Newbridge Financial Services Group Inc. purchased a new position in United Therapeutics during the fourth quarter valued at approximately $25,000. Millstone Evans Group LLC purchased a new position in shares of United Therapeutics during the 4th quarter valued at $67,000. MassMutual Private Wealth & Trust FSB increased its stake in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 58 shares during the last quarter. Anchor Investment Management LLC increased its stake in shares of United Therapeutics by 12.0% in the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 30 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its holdings in shares of United Therapeutics by 678.9% during the fourth quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 258 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on UTHR. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, UBS Group lifted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Trading Down 0.2 %

NASDAQ UTHR opened at $284.73 on Friday. United Therapeutics Co. has a 1 year low of $233.28 and a 1 year high of $417.82. The company has a fifty day simple moving average of $316.61 and a 200 day simple moving average of $348.63. The company has a market cap of $12.79 billion, a P/E ratio of 12.50, a P/E/G ratio of 0.97 and a beta of 0.63.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. During the same period in the prior year, the company earned $4.36 earnings per share. Equities research analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now directly owns 2,577 shares in the company, valued at $940,373.07. This trade represents a 79.51 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. The trade was a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 91,500 shares of company stock worth $30,971,540 in the last 90 days. 11.90% of the stock is owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.